The Board of Directors has appointed Professor Börje Haraldsson as CEO of the company.

“I and the Board as a whole are delighted that Börje Haraldsson is expanding his involvement in Oncorena and takes on the role as CEO of the company. Oncorena is now entering a dynamic clinical phase where all R&D aspects will be managed, so Börje’s experience of managing projects and companies fits fantastically well with the company’s strategy. I also look forward to taking part of Börje’s leadership and the development of the Oncorena team,” says Oncorena’s Chairman Andreas Segerros. “There is a high unmet medical need for better treatment options for patients with advanced kidney cancer undergoing dialysis and we hope that our clinical development work will benefit patients in the future. I would like to take this opportunity to thank Lars Grundemar for his contribution to Oncorena’s growth phase, from preclinical to clinical phase, and wish him every continued success.”

He thus succeeds Dr. Lars Grundemar, who will leave the company.

Börje Haraldsson

Professor Börje Haraldsson is one of the founders of Oncorena. He has played a crucial role in the development of Oncorena’s drug candidate orellanine and is considered a world leader in clinical and experimental renal research, states the company in a press release. Since February 2022, he has been Chief Scientific Officer and part of the company’s management team. Prior to that he held a management position at Novartis in Basel, Switzerland.

”It is with humble gratitude that I have recognized the confidence of the Board. Under Lars Grundemar’s leadership, Oncorena has secured Series A funding and initiated the first clinical study. Thanks to this, the company is well positioned when I now take over the CEO role,” says Börje Haraldsson.

Photo of Börje Haraldsson: Oncorena